Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major

Panminerva Medica

Volumn 51, Issue 1, 2009, Pages 17-23

  Pietrapertosa, A C ^a   Minenna, G ^a   Colella, S M ^a   Santeramo, T M ^a   Renni, I R ^a   D'Amore, M ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Beta thalassemia; Bone density; Osteoporosis; Osteoprotegerin; RANKL ligand

Indexed keywords

BIOLOGICAL MARKER; ESTRADIOL; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TESTOSTERONE; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD; BONE DENSITY; CASE CONTROL STUDY; FEMALE; HUMAN; HYPOGONADISM; MALE; OSTEOPOROSIS; PATHOLOGY;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BONE DENSITY; CASE-CONTROL STUDIES; ESTRADIOL; FEMALE; HUMANS; HYPOGONADISM; MALE; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; TESTOSTERONE; YOUNG ADULT;

EID: 67650273375     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Olivieri NF, Nathan DG, Mac Millan JH, Wayne AS, Liu PP, McGee A et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574-8.
2. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A et al. High prevalence of low bone mass in thalassemia major Br JHaematol 1998;103:911-5.
3. Wonke B. Bone disease in p-thalassemia major. Br J Haematol 1998;103:897-901.
4. Singer ST, Vichinsky EP. Bone disease in P-Thalassemia. Lancet 1999;354:881-2.
5. Grant SFA, Reid DM, Blake G, Herd R, Fogelman I, Ralston SH. (1996) Reduced bone density an osteoporosis associated with polymorphic Spl binding site in the collagen type al gene. Nat Genet 1996;1:203-5.
6. Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D' Agruma L et al. Osteoporosis in beta-thalassemia major patients: analysis of the genetic background. Br J Maematol 2000;111: 461-6.
7. De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR et al. Growth and development in thalassemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 1996;155:368-72.
8. Bekheirnia MR, Abllah Shahirsaz A, Kamgar M, Bouzari N, Erfanzadeh G, Pourzahedgilani N et al. Serum zinc and its relation to bone mineral density in beta-thalassemic adolescent Biol Trace Elem Res 2004;97:215-24.
9. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A et al. Bone resorption is increased in Young adults with Thalassemia Major. Br J Haematol 2001;112:36-41.
10. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5.
11. HofbauerLC, HeufelderAE. Clinical review 114: Hot Topic. The role of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2000;85:2355-63.
12. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteo-porotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vase Biol 2002;22:549-53.
13. Horowitz MC, Xi Y, Wilson K, Kacena MA. Control of osteoclas-togenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 2001;12:9-18.
14. Jones HD, Kong Y-Y, Penninger JM. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 2002;61(Suppl JJ):32-9.
15. Theill LE, Boyle WJ, Penninger LM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Ann Rev Immunol 2002;20:795-823.
16. World Health Organization Assesement of fracture risks and its application to screening for post-menopausal osteoporosis. Technical Report Series 843. WHO, Geneva; 1994.
17. Eisman JA. Vitamin D receptor gane alleles and osteoporosis: an affirmative view. J Bone Miner Res 1995;10:1289-93.
18. Cooper GS, Unbach DM. Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J Bone Miner Res 1996;11:1841-9.
19. Garnero P, Borel O, Somay-Rendu E, Delmas PD. Vitamin D receptor gene polymorphisms do not predict bone turnover and bone mass in healthy premenopausal woman. J Bone Miner Res 1995;10:1283-8.
20. Sano M, Inoue S, Hosoi T, Ouchi Y, Emi M, Shiraki et al. Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis. Biochem Biophys Res Commun 1995;217:378-83.
21. Kobayashi S, Hosoi T, Ouchi Y, Shiraki, Orimo H. Association of bone mineral density with polymorphisms of the estrogen receptor gene in post-menopausal women. J Bone Miner Res 1996;11:306-11. javascript:PopUpMenu2- Set(Menu8852941);
22. Anapliotou MLG, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitrou P. The contribution of hypogonadism to the development of osteoporosis in thalassemia major; new therapeutic approaches. Clini Endocrinol 1995;42:279-87.
23. Lasco A, Morabito N, Gaudio A, Buemi N, Wasniewska M, Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 2001;12:570-5.
24. Voskaridou E, Terpos E, Spina G, Palermos J, Rahetmulla A, Loutradi A et al. Pamidronato is an effective treatment for osteoporosis in patients with beta-thalassemia. British Journal of Haematology 2003;123:730-7.
25. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Min Res 2004;19:722-7.
26. Voskaridou E, Terpos E. Osteoprotegerin to soluble receptor activator of nuclear factor k-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. Eur J Haematol 2005;74:359-61.
27. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A et al. Immunological Characterization of circulating osteoprote-gerin/ osteoclastogenesis inhibitory factor: Increased serum con-cetrations in postmenopausal women with osteoporosid. J Bone Miner Res 1999;14:518-27.
28. Rogers A, Saleh G, Harmon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002;87:4470-5.
29. Riggs BL. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 2000; 106:1203-4.
30. Spelberg TC, Subramaniam M, Riggs BL, Khosla S. The actions and interactions of sex steroids and growth factors/cytochines on the skeleton. Mol Endocrinol 1999;13:819-28.
31. Hofbauer LC Hicok KC, Chen D, Khosla S. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. Eur J Endocrinol 2002;147:269-73.
32. Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytochine levels in normal elderly men. J Clin Endocrinol Metab 2002;87:1550-4.
33. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: Correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001;86:3162-5.
34. Abdollah Shamshirsaz A, Bekheirnia MR, Kamgar M, Pourzahed-gilani N, Bouzari N, Habibzadeh M etal. Metabolic and endocrino-logic complications in beta thalassemia major: a multicenter study in Teheran. BMC Endocr Disord 2003;3:1-6.
35. Angastiniotis M, Pavlides N, Aristidou K, Kanakas A, Yerakaris M, Eracleous E et al. Bone pain in thalassaemia: assessment of DEXA and MRI findings. J Pediatr Endocrinol Metab 1998;ll(Suppl 3):779-84.